Echocardiography Clinical Trial
— CITE-LAOfficial title:
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function
Verified date | October 2023 |
Source | University Hospital "Sestre Milosrdnice" |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Ibrutinib is an irreversible Bruton tyrosine-kinase inhibitor. In prospective studies, the ibrutinib efficacy in the treatment of various B-cell malignancies was established. Different ibrutinib side-effects have been found: diarrhea, arthralgia, infections, neutropenia, hypertension and increased risk of bleeding. Most of the mentioned side-effects were <3rd degree of severity and mostly didn't require dose adjustment or therapy discontinuation. Also, there was an increase in the incidence of atrial fibrillation (AFib) (6-16%). The AFib pathogenesis in this patient population is not clarified, but there are indications that ibrutinib inhibits phosphoinositide-3-kinase (PI3K)-Akt signal-pathway expressed in the myocytes. Regardless of the molecular pathogenesis, the clinical effect of ibrutinib on the myocardium, especially the left atrium, has not been studied. Hence, the aim of this study is to determine the ibrutinib effect on echocardiographic parameters of left atrial function. This study will be performed as a clinical, prospective, observational cohort study with a structured follow-up period of 12 months. All consecutive patients with hemato-oncologic diseases (including chronic lymphocytic leukemia, Mantle-cell lymphoma, Waldenstrom macroglobulinemia, etc.) prescribed with chronic ibrutinib therapy, who are able to understand and sign informed consent, will be enrolled. Primary objective is change of the left atrial function measured by the decrease of the left atrial strain deformation > 10%. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total). Standardized statistical methods and tests will be done using SPSS Version 22.0 or newer. This unique study offers the possibility to show the long-term effect of chronic ibrutinib therapy on left atrial function assessed by transthoracic echocardiography. This observational data is needed to further refine the treatment of these patients and to prevent possible side-effects of ibrutinib which could endanger this specific patient population.
Status | Completed |
Enrollment | 40 |
Est. completion date | March 4, 2023 |
Est. primary completion date | March 4, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - patients with haemato-oncologic diseases (including chronic lymphocytic leukemia, Mantle-cell lymphoma, Waldenstrom macroglobulinaemia, etc.) - patients prescribed with chronic ibrutinib therapy - patients who are able to understand and sign informed consent Exclusion Criteria: - patients with haemato-oncologic diseases who were prescribed with concomitant chemotherapy which can impact left atrial function - patients < 18 years old - patients with known or at initial echocardiography established dilated cardiomyopathy with left ventricular ejection fraction < 35% - patients with permanent atrial fibrillation and dilated left atrium or dilated both atriums - patients implanted with cardiac implantable electronic devices - patients who underwent cardiac surgery - patients with congenital heart diseases (surgically corrected or not) - patients with severe valvular pathology - patients with terminal renal disease - patients with chronic obstructive pulmonary disease - GOLD grade 4 - patients with life expectancy < 12 months - patients not willing to undergo clinical follow-up or sign informed consent - patients recruited in another clinical study |
Country | Name | City | State |
---|---|---|---|
Croatia | Sestre milosrdnice University Hospital | Zagreb |
Lead Sponsor | Collaborator |
---|---|
University Hospital "Sestre Milosrdnice" |
Croatia,
Boriani G, Corradini P, Cuneo A, Falanga A, Foa R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL. Practical management of ibrutinib in the real life: Focus on atr — View Citation
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schu — View Citation
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, — View Citation
Deeks ED. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia. Drugs. 2017 Feb;77(2):225-236. doi: 10.1007/s40265-017-0695-3. — View Citation
Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 2017 Jul;96(7):1175-1184. doi: 10.1007/s00277-017-2973-2. Epub 2017 Mar 24. — View Citation
Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016 Jul 7;128(1):138-40. doi: 10.1182/blood-2016-05-712828. Epub 2016 May 31. No abstrac — View Citation
Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes M, Nabhan C, Ali N, Schuster S, Carver J. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer — View Citation
O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. Safety Analysis of Four Randomized Controlled Studi — View Citation
Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, Massari F, Cortelezzi A. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol. 2018 Jun 11;11(1):79. doi: 10.1186/s13045-018-0626-0. — View Citation
Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15. — View Citation
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCa — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | left atrial function change | change of the left atrial function measured by the decrease of the left atrial strain deformation > 10% assessed by transthoracic echocardiography | initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy | |
Secondary | left ventricular ejection fraction change | measurement of left ventricular systolic function change assessed by transthoracic echocardiography - method according to Simpson and Teicholz | initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy | |
Secondary | left ventricular diastolic function change | measurement of left ventricular diastolic function change assessed by transthoracic echocardiography (E/A and E/E') | initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy | |
Secondary | left atrial volume change | 2D and 3D left atrial volume change assessed by transthoracic echocardiography + left atrial dimension in PLAX and 4 chamber projection | initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy | |
Secondary | P wave duration change | P wave duration and PQ interval duration change assessed in 12-lead electrocardiogram (in milliseconds) | initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy | |
Secondary | left atrial pump function change | left atrial ejection fractionchange assessed by transthoracic echocardiography (doppler strain measurement method) | initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy | |
Secondary | atrial fibrillation incidence | incidence of paroxysmal atrial fibrillation assessed by symptoms + ECG or 24-hours Holter-ECG | initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04083924 -
Preclinical Medical Student Echocardiography Training American Society of Echocardiography Curriculum
|
N/A | |
Recruiting |
NCT05778500 -
Algorithms to Improve the Accuracy of the Echocardiographic Report
|
||
Completed |
NCT04925245 -
Clinical Reminder to Improve Appropriateness of Echocardiography
|
N/A | |
Completed |
NCT02000492 -
Frequent Ballgames Training for 9-11 Year Old Schoolchildren
|
N/A | |
Recruiting |
NCT05055089 -
Short- and Medium-term Results of New Generation Aortic
|
||
Completed |
NCT04334733 -
The Impact of Preprocedural Animation About Echocardiography Display and Kaleidoscope Display on Anxiety in Children
|
N/A | |
Recruiting |
NCT06106178 -
A Novel Serious Game as an Alternative for Teaching Basic Point-of-Care Transthoracic Echocardiography Skills
|
N/A | |
Completed |
NCT05103189 -
4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension
|
N/A | |
Completed |
NCT03221205 -
Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients
|
N/A | |
Not yet recruiting |
NCT03638245 -
Evaluation of the Fetal MPI in Abnormal Cardiotocography Cases in 3rd Trimester of Pregnancy and Fetal Outcome.
|
||
Recruiting |
NCT04395014 -
Echocardiographic Assessment of Ventricular Strain During a Healthy Pregnancy in the First, Second, and Third Trimester.
|
||
Withdrawn |
NCT03133962 -
Evaluation of the Contribution of the Ultrasound Tracking and the Positioning of the Distal End During the Implantation of Implantable Chamber or Long-lasting Venous Catheter
|
N/A | |
Completed |
NCT04366453 -
Evaluation of LVEF by a New Automatic Evaluation Tool in a Pocket Ultrasound Scanner
|
N/A | |
Recruiting |
NCT05462301 -
Normal Reference Range for Neonatal Echocardiography
|
||
Withdrawn |
NCT04810520 -
Live Stream of Prehospital point-of Care Ultrasound by Air Rescue Physicians
|
||
Recruiting |
NCT03464591 -
Cardiac Speckle Tracking Myocardial Strain Balance
|
||
Completed |
NCT04419662 -
Evaluation of Patients After Cardiac Surgery: Novel Ultrasound Parameters for Quantification of Renal Perfusion & Analysis of Phenylephrines' Effect on Invasive Haemodynamics and Echocardiographic Measures
|
Phase 4 | |
Completed |
NCT00730964 -
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
|
Phase 4 | |
Completed |
NCT06330103 -
Efficacy of AI EF Screening by Using Smartphone Application Recorded PLAX View Cardiac Ultrasound Video Clips
|
N/A | |
Not yet recruiting |
NCT05306730 -
Echocardiography by Non-cardiologist in Early Management of Patients With Chest Pain
|
N/A |